Recent

% | $
Quotes you view appear here for quick access.

Spherix Incorporated Message Board

  • m_cansun m_cansun Feb 26, 2003 11:31 AM Flag

    WallStreetReporter interv.Gilbert Levin

    The audio interview is located on wallstreetreporter .com, very informative...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Rpal/J6Pack et al.. I think the interview was really good, however concerning a press release..

      this board, and particular investors on this board with a big holding in SPEX, have tried everything to get SPEX to do a press release, especially a few weeks ago when the stock took a sharp fall. Our efforts did not and could not have went un-noticed.

      However I now firmly believe that SPEX and ARLA are contractually bound to stay silent on events, so that Tag customers get the glory, of launching a new product, with all the Tag benefits mentioned, but wih Tag in small print in the ingredients.

      I think this interview was the Docs way around the 'silence' and at the same time letting us know on the QT.. to hang in tight. He said more in that interview, than in the last 6 months on the SPEX site.

      "Say nothing to yee see Claude.."

      sl�n Doiremik

    • Please add any comments you might have regarding the interview. I just don't have the time now to listen to the entire interview.

    • Great interview in which Gil says, among other things:

      1. There is a very large target market for Tagatose; will be on the market in a "couple of months" and SPEX will soon be receiving royalties

      2. Tagatose has a number of advantages (e.g.
      does not produce glucose levels in the blood and in fact reduces glucose levels for several hours, tagatose goes a long way to curing symnptoms of type 2 diabetes)

      3. Tagatose does not cause tooth decay

      4. Spex retains rights to drug use and cosmetic use, such as in toothpaste and mouthwash. Successful tests have been conducted by major manufacturers

      5. Spex is working on a separate source of supply for nonfood uses

      I have not listened to the entire interiew yet. More later.

      • 1 Reply to rpal3
      • I finished listening to the interview; to recap, this is what Dr. Levin said:

        1. There is a very large target market for Tagatose; will be on the market in a "couple of months" and SPEX will soon be receiving royalties.

        2. Tagatose has a number of advantages (e.g.
        does not produce glucose levels in the blood and in fact reduces glucose levels for several hours, tagatose goes a long way to curing symnptoms of type 2 diabetes)

        3. Tagatose does not cause tooth decay

        4. Spex retains rights to drug use and cosmetic use, such as in toothpaste and mouthwash. Successful tests have been conducted by major manufacturers.

        5. Spex is working on a separate source of supply for nonfood uses.

        6. Spex had, as of 9/30/02, some 8 million in cash and cash equivalents, of which $5 million is earmarked for development of Tagatose.

        7. Only one analyst follows SPEX (Wellington). Others mistakenly overlook the fact that Tagatose is not like other sweeteners, in part because it is a bulk sweetener (i.e. can be used in cake and candy for required bulk).

        8. Information services division: SPEX entered 2003 with biggest backlog in its history. Will proceed with "full court press", e.g. in commerical division.

        9. The Doc sees SPEX as a very good investment. He notes that shareholders are too focused on Tagatose and overlook the strength of SPEX' other products and services.

        Great interview; now, let's ask the Doc to put the gist of his interview in an appropriate press release.

 
SPEX
2.53-0.35(-12.15%)May 26 4:00 PMEDT